Crohn's Disease News and Research

Latest Crohn's Disease News and Research

Rebirth of the cursed drug Thalidomide

Thalidomide was once a dreaded name in the Pharmaceutical industry. It was initially marketed in some European countries nearly 5 decades back as a sedative and after millions of pregnant women took it for morning sickness it had devastating results on the babies. The babies were born with flippers instead of limbs a condition known as phocomelia. Since then it has been under strict control.

5 Apr 2010

Variant of ATG16L1 gene associated with higher risk for Crohn's disease

The ATG16L1 gene is located on chromosome 2 and encodes a protein involved in the formation of autophagosomes during autophagy. Autophagy is a cytoplasmic process that keeps a cell stable. Hampe et al first identified ATG16L1 as a Crohn's disease (CD) susceptibility gene in 2007, and many other studies have arisen since then. However, the definite relationship of variants of ATG16L1 with IBD remains unclear.

2 Apr 2010

DNA resources coupled to EMR systems hold potential as valuable tools for clinical research

A new study reveals an exciting potential benefit of the rapidly accumulating databases of health care information, the ability to make unprecedented links between genomic data and clinical medicine. The research, published by Cell Press in the April issue of the American Journal of Human Genetics, supports the idea that large scale DNA databanks linked to electronic medical record (EMR) systems provide a valuable platform for discovering, assessing and validating associations between genes and diseases.

2 Apr 2010

2010 DDW conference to highlight breakthrough research on GI health

Thousands of physicians, researchers and academics from around the world will gather in New Orleans in early May for Digestive Disease Week- (DDW-), the premiere scientific conference in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.

2 Apr 2010

New book from AGA helps patients self-manage their IBD and challenges

Inflammatory bowel disease strikes young people between the ages of 15 and 30 most often, but it can appear at any age. It is easy to for the 100,000 people diagnosed with IBD - Crohn's disease and ulcerative colitis - each year to feel powerless against this condition, but now, a new book from the AGA helps patients self-manage their IBD and the challenges they face.

1 Apr 2010

Eisai Europe seeks EMA approval of eribulin mesylate for locally advanced or metastatic breast cancer

Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as 'E7389', for the treatment of locally advanced or metastatic breast cancer in Europe. Eribulin mesylate, a non-taxane microtubule dynamics inhibitor, is an investigational chemical compound discovered and developed by Eisai. Regulatory applications for eribulin mesylate have also been submitted in the United States and Japan.

31 Mar 2010

Resurgence of mumps orchitis among teenage boys and young men

Urologists at a leading Irish hospital have reported an alarming increase in the number of teenage boys and young men developing mumps orchitis, in a paper published in the April issue of the urology journal BJUI.

30 Mar 2010

NYU researchers identify novel therapy for rheumatoid arthritis

By enhancing the activity of immune cells that protect against runaway inflammation, researchers at NYU Langone Medical Center may have found a novel therapy for rheumatoid arthritis and other autoimmune diseases.

26 Mar 2010

T1D and IBD may respond to 2-way genetic switch: Study

Pediatric researchers analyzing DNA variations in type 1 diabetes and inflammatory bowel disease have found a complex interplay of genes. Some genes have opposing effects, raising the risk of one disease while protecting against the other. In other cases, a gene variant may act in the same direction, raising the risk for both diseases.

23 Mar 2010

ChemoCentryx undertakes Phase II clinical trial of CCX140

ChemoCentryx, Inc., today announced that it has undertaken a Phase II clinical trial of CCX140, a novel, orally-available small molecule compound designed to specifically target the chemokine receptor known as CCR2.

22 Mar 2010

AARDA launches campaign on family AQ

In honor of the designation of March as National Autoimmune Disease Awareness Month by the U.S. Senate on March 4, 2010, the American Autoimmune Related Diseases Association (AARDA) wants to help you learn your family's AQ. AQ is a play on IQ that stands for Autoimmune Quotient. It's about knowing how likely you or a loved one is to develop an autoimmune disease, based on the prevalence of these diseases and your family history. The campaign features AARDA National Spokesperson and Actress Kellie Martin, best known for her memorable roles on "E.R." and "Life Goes On."

22 Mar 2010

For undecided lawmakers, health care bill is personal

Politico: The decision on how to vote on the health care overhaul affects members differently than nearly any other issue. "[N]o other single issue — civil rights, Medicare, even war in this age of professional armies — quite matches the personal side of health care's stubborn details. … Everybody gets sick; everybody dies.

20 Mar 2010

Genes role in protecting intestinal tract from colitis may lead to potential targets for treatment

Scientists report a protein made by a gene already associated with a handful of human inflammatory immune diseases plays a pivotal role in protecting the intestinal tract from colitis.

19 Mar 2010

Almost 62% of Canadians age 65 and older use five or more classes of prescription drugs: CIHI study

Almost two-thirds (62%) of Canadians age 65 and older living in the community in six provinces are using five or more classes of prescription drugs, according to a study released today by the Canadian Institute for Health Information.

19 Mar 2010

Survey unveils impact of gene regulation on human health

Researchers are only beginning to understand how individual variation in gene regulation can have a lasting impact on one's health and susceptibility to certain diseases. Now, an ambitious survey of the human genome has identified differences in the binding of master regulators called transcription factors to DNA that affect how genes are expressed in different people.

19 Mar 2010

Viron Therapeutics' VT-346 anti-TNF protein exhibits positive results in transgenic mouse model for arthritis

Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis. VT-346 achieved a statistically significant, dose dependent impact in this preclinical model of arthritis and prevented deterioration due to disease in terms of weight gain, arthritic score and pathology parameters. VT-346 had particularly strong protective effects on therapeutically-important bone and cartilage damage in this model.

16 Mar 2010

Liquid CMO seeks osteoarthritis and fibromyalgia patients for pilot study in Phoenix

Makers of a new liquid natural supplement formulation of Cetyl-Myristoleate (CMO) are seeking osteoarthritis and fibromyalgia patients for a pilot study in Phoenix beginning Monday, April 12, 2010.

16 Mar 2010

XOMA 052 reduces adverse consequences that lead to development of congestive heart failure

XOMA Ltd., a leader in the discovery and development of antibody therapeutics, announced results demonstrating that a murine equivalent of XOMA 052, its novel, high-affinity antibody to interleukin-1 beta (IL-1 beta), significantly reduced adverse consequences that usually lead to the development of congestive heart failure in a mouse model of acute myocardial infarction (heart attack).

15 Mar 2010

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the initiation of a Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. Funding for the trial is being provided by the Juvenile Diabetes Research Foundation International, the largest patient advocacy organization of Type 1 diabetes research worldwide.

12 Mar 2010

New MMMCC center improves patients’ access to medical marijuana

Marijuana is not just for brownies anymore. It has touched the lives of thousands of Michigan residents who are struggling with chronic pain, severe nausea, seizures, spasms or wasting syndrome.

12 Mar 2010